Wechselwirkungen · Mvasi
MVASI 25 mg/mL concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 11
HOS-140881 · Präparat HOS-098594
No interaction studies have been performed. EGFR monoclonal antibodies should not be administered for the treatment of mCRC in combination with bevacizumab-containing chemotherapy. Results from the randomised phase III studies, PACCE and CAIRO-2, in patients with mCRC suggest that the use of anti-EGFR monoclonal antibodies panitumumab and cetuximab, respectively, in combination with bevacizumab plus chemotherapy, is associated with decreased progression-free survival (PFS) and/or overall survival (OS), and with increased toxicity compared with bevacizumab plus chemotherapy alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cetuximab (HOS-113159) panitumumab (HOS-113539)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-08T12:03:00Z · SHA-256 7315a0f92d93f32ff51c381d8e3464645773cd3c5a1bc96a97e09c6d6939e82e · Passage d4d2cfaa0403ea41a491c346f0355d7e5438529e9eae169e38923ac2407bc720 · Zeichen 2398–2984 im Abschnitt